Features:
-Nonpathogenicwithleastimmuneresponseandbestsuitableforinvivoapplication.
-Excellentgenedeliveryefficiencyinmostcelltypesincludingdividingandnon-dividingorprimarycells.
-Persistenttransgeneexpression.
-MultipleSEROtypes(AAV-1,AAV-2,AAV-3,AAV-4,AAV-5,AAV-6,AAV-7,AAV-8,AAV-9,AAV-DJ/8andAAV-DJ).
ServiceDescription:
-rAAVpackagingin2xcellstack.
-rAAVpurificationviaadvanced2xCsClultra-centrifugation.
-Desalting,filtersterilizationandAAVtitrationviaqPCR.
rAAVSerotypesWeOffer:
AAV-1,AAV-2,AAV-3,AAV-4,AAV-5,AAV-6,AAV-7,AAV-8,AAV-9,AAV-PHP.B,AAV-DJ/8andAAV-DJ.
RequiredMaterials:
AAVcisplasmidcarryingyourgeneofinterest(GOI),>300µg.
TurnaroundTime:1~2weeks.
Deliverables:>1.0mLofsuperpurifiedinvivograderAAVvectorat>1E+13VG/mL*.
Weofferdiscountfornewcustomer,pleaserequestaquotewithustoday.
ServiceInquiry/RequestaQuote
SuperHighYield:
WithourproprietarygeneticallyengineeredAAV·HTpackagingcellandamodifiedrAAVcisvector,therAAVyieldiseasytoreachsuperhighlevel--------total1E+15VG.ForsuperhighlevelrAAVproductionupto1E+15VGtotal,pleasecontactustorequestaquote.
Figure1.AcomparisonofpurityandinfectivityofrAAVvectorsfromdifferentsourcesshowingsuperpurifiedandsuperinfectious(closetoclinicaltrialgrade)rAAVvectorpreparedviaouradvanceddoubleCsClultra-centrifugationapproach.
A.rAAVvectors(total1E+9VGperlane) fromdifferentsourceswereresolvedonSDS-PAGEfollowedbysilverstaining. Lane1:GMPmanufacturedrAAVvectorfromCHOP;Lane2:rAAVpreparedviaouradvanced2xCsClultra-centrifugationapproach;Lane3:rAAVfromVectorCoreofBCM;Lane4:rAAVfromourcompetitor"V";Lane5:rAAVfromourcompetitor"C";Lane6:ProteinMarker.
B.SuperinfectiousrAAVvectorpreparedviaadvanceddoubleCsClultra-centrifugation. Leftpanel:rAAV9-GFP(total5E+9VG)fromourcompetitor"V"injectedtomouseeye;Rightpanel:rAAV-9-GFP(total5E+9VG)purifiedviaadvanced2xCsClultra-centrifugationinjectedtomouseeye. 
Figure2.AcomparisonofinfectivityofrAAVvectorsfromdifferentsourcesshowingsuperpurifiedrAAVpreparedviaadvanceddoubleCsClultra-centrifugationapproachissuperinfectious.
rAAV1-GFP(total2E+9VG)fromdifferentsourceswereinjectedtomousemuscletissue. TheGFPfluorescencewasvisualized3weekspostinjection. A.rAAV1-GFPfromourcompetitor"V";B.rAAV1-GFPfromourpre-maderAAVsstockpurifiedviaadvanceddoubleCsClultra-centrifugation. C.QuantificationdatashowedthatoursuperpurifiedrAAV(bar2)is~9timesmoreinfectiousthanthat(bar1)preparedviaconventionalCsClultra-centrifugation.
*Finalviralyieldmaydependonthenatureoftransgene.
